Trial
NCT02010567
Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
UNC Lineberger Comprehensive Cancer Center
Collaborators
Cerulean Pharma Inc.
Condition
Rectal Cancer
Intervention
CRLX101
Why stopped
The study was halted prematurely at the funding partner's request.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-11-03